On Tuesday, H.C. Wainwright initiated coverage on shares of Voyager Therapeutics (NASDAQ:VYGR), a biotechnology company specializing in treatments for central nervous system (CNS) diseases. The firm set a Buy rating on the stock with a price target of $30.00.
Voyager Therapeutics, established in 2014, is recognized for its pioneering work in gene therapy (GT), RNA interference (RNAi), and neuroscience. The company's focus is on developing innovative treatments for CNS conditions with validated targets and biomarkers.
One of the key technologies Voyager is advancing is its TRACER capsid discovery platform. This platform is designed to create novel capsids with enhanced affinity for the CNS, which are critical components of GT products.
In addition to its GT technology, Voyager has a wholly-owned pipeline that includes an anti-tau monoclonal antibody (mAb) program targeting Alzheimer’s disease (AD). The expectation is that this will be complemented by a combination approach with potentially best-in-class in vivo GTs, including a vectorized antibody program aimed at tau and amyloid-beta (Aβ) proteins.
Voyager's strategic partnerships have been a significant aspect of its development strategy. The company has collaborated with leading pharmaceutical firms such as Novartis (SIX:NOVN), Neurocrine (NASDAQ:NBIX), Sangamo, and Alexion (NASDAQ:ALXN), a subsidiary of AstraZeneca (NASDAQ:AZN). These partnerships are anticipated to create substantial long-term value for Voyager's shareholders.
H.C. Wainwright forecasts that Voyager's owned and partnered programs will lead to at least four Investigational New Drug (IND) filings between 2024 and 2025. This could provide key clinical proof-of-biology data as early as 2025, which would further validate Voyager's technological platform.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.